Kalaris Therapeutics (NASDAQ:KLRS) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Kalaris Therapeutics (NASDAQ:KLRS) from a hold rating to a sell rating in a research report report published on Sunday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Kalaris Therapeutics Stock Performance

NASDAQ:KLRS opened at $1.87 on Friday. Kalaris Therapeutics has a 52 week low of $1.78 and a 52 week high of $11.88. The stock’s fifty day moving average is $2.67 and its two-hundred day moving average is $5.19.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06. Equities research analysts predict that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Kalaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in KLRS. Sigma Planning Corp acquired a new stake in Kalaris Therapeutics during the second quarter worth approximately $41,000. WealthTrust Asset Management LLC acquired a new position in shares of Kalaris Therapeutics in the 1st quarter valued at $72,000. Velan Capital Investment Management LP boosted its holdings in shares of Kalaris Therapeutics by 38.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after buying an additional 7,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $122,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $122,597. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina. Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.